• Dr. Manne obtained his M.S. (Biochemistry, Histochemistry, Parasitology, Zoonosis) and Ph.D. (energy metabolic pathways of endoparasites) degrees from Osmania University, Hyderabad, India. His postdoctoral training was in molecular immunology and vaccine development for malaria (Malaria Research Center, Delhi, India); in helicobacter infections (School of Microbiology, University of New South Wales, Sydney, Australia); and in histopathology, molecular tumor biology, and preclinical translational research of human malignancies at the University of Alabama at Birmingham (UAB). He also received certification in bioinformatics at UAB. Dr. Manne’s research on racial disparity in CRC has received considerable national and international recognition. In 2009, the Presidents Cancer Panel invited Dr. Manne to speak on “Biologic differences between ethnic groups and their clinical implications in cancer care,” and devoted to the topic, “America’s demographic and cultural transformation: implications for the cancer enterprise.” Currently, he is the Lead Principal Investigator of two Comprehensive Cancer Research Partnership between UAB Comprehensive Cancer Center and Tuskegee University, Tuskegee, AL and Morehouse School of Medicine, Atlanta, GA (U54); and Alabama State University, Montgomery, AL (P20) to Reduce Cancer Health Disparities by implementing innovative, multi-disciplinary, collaborative, population-based cancer control and prevention research and has contributed to education, training, and community outreach activities. These two programs are funded by the National Cancer Institute of the National Institute of Health.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Molecular Characterization of Visible Low Grade Dysplastic lesions in Patients with Inflammatory Bowel disease.Human Pathology2023
    2023 Identification of androgen response-related lncRNAs in prostate cancer 2023
    2022 A high-resolution 3D atlas of the spectrum of tuberculous and COVID-19 lung lesionsEMBO Molecular Medicine.  14. 2022
    2022 African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African DescentCancer Discovery.  12:2530-2551. 2022
    2022 Developing 3D Organoid Raft Cultures from Patient-Derived Xenografts as Rapid Models to Screen Efficacy of Experimental TherapeuticsInternational Journal of Molecular Sciences.  23. 2022
    2022 A signature of Prevotella copri and Faecalibacterium prausnitzii depletion, and a link with bacterial glutamate degradation in the Kenyan colorectal cancer patientsJournal of Gastrointestinal Oncology.  13:2282-2292. 2022
    2022 ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsJCI Insight.  7. 2022
    2022 Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer and borderline pancreatic inoperable cancers.Journal of Clinical Oncology.  40:e16253-e16253. 2022
    2022 Reducing regorafenib toxicity by combining with dual JAK-HDAC inhibitor in colorectal cancer.Journal of Clinical Oncology.  40:e15597-e15597. 2022
    2022 Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemicBMJ Open.  12. 2022
    2022 DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancerMolecular Oncology.  16:1728-1745. 2022
    2022 UALCAN: An update to the integrated cancer data analysis platformNeoplasia.  25:18-27. 2022
    2022 Understanding the significance of biological clock and its impact on cancer incidenceCancer Letters.  527:80-94. 2022
    2022 Gastrointestinal Manifestations of COVID-19 Infection: Clinicopathologic Findings in Intestinal Resections Performed at Single InstitutionFrontiers in Medicine.  9. 2022
    2022 GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells 2022
    2022 The interplay of pineal hormones and socioeconomic status leading to colorectal cancer disparityTranslational Oncology.  16. 2022
    2022 Age-Dependent Heterogeneity of Lymph Node Metastases and Survival Identified by Analysis of a National Breast Cancer Registry. 2022
    2022 Serine-threonine Kinase Receptor-Associated Protein is a Critical Mediator of APC Mutation–Induced Intestinal Tumorigenesis Through a Feed-Forward MechanismGastroenterology.  162:193-208. 2022
    2021 Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cellsScientific Reports.  11. 2021
    2021 Corrigendum to ‘Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model’ [Translational Oncology 13 (2020) 100754] (Translational Oncology (2020) 13(4), (S1936523320301030), (10.1016/j.tranon.2020.100754))Translational Oncology.  14. 2021
    2021 Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancerFrontiers in Bioscience-Landmark.  26:765-776. 2021
    2021 Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinomaTranslational Oncology.  14. 2021
    2021 Gastric Sclerosing Epithelioid Fibrosarcoma Harboring a Rare FUS-CREM FusionInternational Journal of Surgical Pathology.  29:565-570. 2021
    2021 Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistentCancer Medicine.  10:5712-5720. 2021
    2021 Abstract LB245: TRIM29 mediates metastasis though hypoxia-regulated proteins in microsatellite-stable and p53-mutated colorectal cancersCancer Research.  81:lb245-lb245. 2021
    2021 Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian WomenTranslational Oncology.  14. 2021
    2021 Age-dependent heterogeneity of lymph node metastases and survival identified by analysis of a national breast cancer registry 2021
    2021 Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic. 2021
    2021 ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition 2021
    2021 Expression of trefoil factor 3 is decreased in colorectal cancer 2021
    2021 Optimum health and inhibition of cancer progression by microbiome and resveratrolFrontiers in Bioscience-Landmark.  26:496-517. 2021
    2021 Positive Retrospective SARS-CoV-2 Testing in a Case of Acute Respiratory Distress Syndrome of Unknown Etiology.Case Reports in Pulmonology.  2021. 2021
    2020 TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability statusMolecular Oncology.  14:3007-3029. 2020
    2020 Identification of Prognostic Markers in Cholangiocarcinoma Using Altered DNA Methylation and Gene Expression ProfilesFrontiers in Genetics.  11. 2020
    2020 Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast CancerFrontiers in Immunology.  11. 2020
    2020 Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer ProgressionInvestigative urology.  204:622-623. 2020
    2020 Cirrhotomimetic hepatocellular carcinoma: experience of a single institution and review of the literature.Hepatic Oncology.  8:HEP28. 2020
    2020 PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its ProgressionTranslational Oncology.  13. 2020
    2020 Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells 2020
    2020 A quantitative centrosomal amplification score predicts local recurrence of ductal carcinoma in situClinical Cancer Research.  26:2898-2907. 2020
    2020 Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progressionOncogene.  39:4077-4091. 2020
    2020 Identification of distinct heterogenic subtypes and molecular signatures associated with african ancestry in triple negative breast cancer using quantified genetic ancestry models in admixed race populationsCancers.  12. 2020
    2020 PAICS, a purine nucleotide metabolic enzyme, is involved in tumor growth and the metastasis of colorectal cancerCancers.  12. 2020
    2020 Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX ModelTranslational Oncology.  13. 2020
    2019 Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity researchCancer.  125:4452-4461. 2019
    2019 Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophagesMolecular Genetics and Genomic Medicine.  7. 2019
    2019 MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal CancerTranslational Oncology.  12:1461-1467. 2019
    2019 Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression 2019
    2019 Abstract 851: MicroRNA-124 modulated collagen-prolyl hydroxylase P4HA1 expression regulates colon cancer progressionCancer Research.  79:851-851. 2019
    2019 Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experienceAnnals of Oncology.  30:iv64. 2019
    2019 Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experienceAnnals of Oncology.  30:iv74. 2019
    2019 Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancerAnnals of Oncology.  30:iv67. 2019
    2019 Prognostic role of androgen receptor in triple negative breast cancer: A multi-institutional studyCancers.  11. 2019
    2019 Stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma: A single institution experienceAnnals of Oncology.  30:iv89. 2019
    2019 Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells.Medicines.  6. 2019
    2019 The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtypePLoS One.  14. 2019
    2019 Advances in pancreatic cancer biomarkersOncology Reviews.  13:69-76. 2019
    2018 Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinomaOncotarget.  9:36836-36848. 2018
    2018 Wnt receptor Frizzled 8 is a target of ERG in prostate cancer 2018
    2018 Detection of BRAF V600E mutations with next-generation sequencing in infarcted thyroid carcinomas after fine-needle aspirationAmerican Journal of Clinical Pathology.  150:177-185. 2018
    2018 Abstract 3495: Trip13, a target of miR192, facilitates colorectal cancer progression through WNT/β-catenin signalingCancer Research.  78:3495-3495. 2018
    2018 Single molecule mtDNA fiber FISH for analyzing numtogenesisAnalytical Biochemistry.  552:45-49. 2018
    2018 miR-34a regulates expression of the stathmin-1 oncoprotein and prostate cancer progressionMolecular Cancer Research.  16:1125-1137. 2018
    2018 Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancerFrontiers in Bioscience-Landmark.  23:1987-2000. 2018
    2018 Prostate cancer health disparities: An immuno-biological perspectiveCancer Letters.  414:153-165. 2018
    2017 Bromoethylindole (BEI-9) redirects NF-κB signaling induced by camptothecin and TNFα to promote cell death in colon cancer cells 2017
    2017 Prolonged exposure of resveratrol induces reactive superoxide species–independent apoptosis in murine prostate cells 2017
    2017 Label-free detection of DNA hybridization with a compact LSPR-based fiber-optic sensor 2017
    2017 Functional consequence of the p53 codon 72 polymorphism in colorectal cancerOncotarget.  8:76574-76586. 2017
    2017 Molecular characterization of pro-metastatic functions of β4- integrin in colorectal cancerOncotarget.  8:92333-92345. 2017
    2017 Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancerOncotarget.  8:20198-20212. 2017
    2017 Resveratrol induces mitochondria-mediated, caspaseindependent apoptosis in murine prostate cancer cellsOncotarget.  8:20895-20908. 2017
    2016 Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and PerspectiveCurrent Colorectal Cancer Reports.  12:332-344. 2016
    2016 A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancerBMC Cancer.  16. 2016
    2016 Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancerCancer Letters.  374:304-314. 2016
    2016 Targeting Hsp70: A possible therapy for cancerCancer Letters.  374:156-166. 2016
    2016 Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. 2016
    2015 Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in acolon-26 tumor-bearing mouse model in vivoCancer Medicine.  4:1767-1780. 2015
    2015 Abstract 2776: Codon 72 and Intron-3 polymorphisms in TP53 are risk factors for breast cancerCancer Research.  2776-2776. 2015
    2015 Abstract 4004: Prognostic value of miRNAs in breast cancer varies with patient race and molecular subtypeCancer Research.  4004-4004. 2015
    2015 Abstract 4953: Molecular and cellular localization profiles of tristetraprolin in colorectal cancer: Implications for tumor progression in diverse patient populationsCancer Research.  4953-4953. 2015
    2015 3-(2-bromoethyl)-indole inhibits the growth of cancer cells and NF-κB activation 2015
    2015 Clinical implications of rabphillin-3A-like gene alterations in breast cancerPLoS One.  10. 2015
    2015 Nanomagnetic levitation three-dimensional cultures of breast and colorectal cancersJournal of Surgical Research.  194:319-326. 2015
    2015 IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cellsBioorganic and Medicinal Chemistry.  23:602-611. 2015
    2015 Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial-to-mesenchymal transition in colon and breast cancersOncotarget.  6:27763-27777. 2015
    2014 Abstract C77: Tristetraprolin suppression is associated with advanced stage colorectal cancerCancer Epidemiology, Biomarkers and Prevention.  23:c77-c77. 2014
    2014 Abstract PR5: Prognostic value of miRNAs in breast cancer: Molecular type and patient raceCancer Epidemiology, Biomarkers and Prevention.  23:pr5-pr5. 2014
    2014 Abstract 3820: Expression of ST6Gal-1 in colorectal cancer and patient prognosisCancer Research.  3820-3820. 2014
    2014 Disparities in cervical cancer mortality rates as determined by the longitudinal hyperbolastic mixed-effects type II modelPLoS One.  9. 2014
    2014 Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugsBMC Cancer.  14. 2014
    2014 A New Robust Method for Nonlinear Regression.Journal of Biometrics and Biostatistics.  5:211. 2014
    2014 Robust Logistic and Probit Methods for Binary and Multinomial Regression.Journal of Biometrics and Biostatistics.  5. 2014
    2013 The Chemokine CXCL8 in Carcinogenesis and Drug Response.ISRN Oncology.  2013:859154. 2013
    2013 Clinical implications of microRNAs in cancer 2013
    2013 Post-transcriptional processing of genetic information and its relation to cancer 2013
    2013 The prognostic value of MicroRNAs varies with patient race/ethnicity and stage of colorectal cancerClinical Cancer Research.  19:3955-3965. 2013
    2013 Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer.Journal of Cancer Therapy.  4:898-906. 2013
    2013 Abstract 1944: Evaluation of the prognostic value of miRNA-181b and its target identification and validation in colorectal cancers.Cancer Research.  73:1944-1944. 2013
    2013 Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53 2013
    2013 Socioeconomic status, p53 abnormalities, and colorectal cancerJournal of Gastrointestinal Oncology.  4:40-44. 2013
    2012 Pseudoangiomatous stromal hyperplasia (PASH) of the breast: A series of 24 patients 2012
    2012 Prognostic significance and gene expression profiles of p53 mutations in microsatellite-stable Stage III colorectal adenocarcinomasPLoS One.  7. 2012
    2012 Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: The role of rs67491583Cancer Genetics.  205:25-33. 2012
    2012 Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells 2012
    2012 MiRNAs are stable in colorectal cancer archival tissue blocksFrontiers in Bioscience (Elite Edition).  4 E:1937-1940. 2012
    2011 Development and progression of colorectal neoplasiaCancer Biomarkers.  9:235-265. 2011
    2011 The biology of incipient, pre-invasive or intraepithelial neoplasiaCancer Biomarkers.  9:21-39. 2011
    2011 Translational pathology of neoplasiaCancer Biomarkers.  9:7-20. 2011
    2011 Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissueJournal of Clinical Oncology.  29:4620-4626. 2011
    2011 Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancerJournal of Hematology and Oncology.  4. 2011
    2011 Abstract 2262: The prognostic value of p53 abnormalities in colorectal cancers varies based on detection methodsCancer Research.  71:2262-2262. 2011
    2011 Erratum: Development of combination tapered fiber-optic biosensor dip probe for quantitative estimation of interleukin-6 in serum samples (Journal of Biomedical Optics (2010) 15 (067005))Journal of Biomedical Optics.  16. 2011
    2010 Bax expression is a candidate prognostic and predictive marker of colorectal cancer.Journal of Gastrointestinal Oncology.  1:76-89. 2010
    2010 Development of combination tapered fiber-optic biosensor dip probe for quantitative estimation of interleukin-6 in serum samplesJournal of Biomedical Optics.  15. 2010
    2010 Standards for immunohistochemical imaging: A protein reference device for biomarker quantitation 2010
    2010 MiRNAs as biomarkers for management of patients with colorectal cancerBiomarkers in Medicine.  4:761-770. 2010
    2010 Prognostic value of mucin 4 expression in colorectal adenocarcinomasCancer.  116:3577-3586. 2010
    2010 Comparison of the predictive qualities of three prognostic models of colorectal cancerFrontiers in Bioscience (Elite Edition).  2 E:849-856. 2010
    2010 Quantitative estimation of IL-6 in serum/plasma samples using a rapid and cost-effective fiber optic dip-probeProceedings of SPIE.  7559. 2010
    2010 Smad signaling is required to maintain epigenetic silencing during breast cancer progressionCancer Research.  70:968-978. 2010
    2009 Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancerCancer.  115:5798-5806. 2009
    2009 HIV Nef-M1 effects on colorectal cancer growth in tumor-induced spleens and hepatic metastasisMolecular and Cellular Pharmacology.  1:85-91. 2009
    2009 Combined effects of formalin fixation and tissue processing on immunorecognition Fixation effects on immunostaining 2009
    2009 Combined effects of formalin fixation and tissue processing on immunorecognition. 2009
    2009 Furthering the evidence-based management of dermatologic effects of EGFR inhibitor therapyCurrent Colorectal Cancer Reports.  5:179-181. 2009
    2009 Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancerJournal of Clinical Oncology.  27:4339-4345. 2009
    2009 Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis.Journal of Clinical Oncology.  27:6027. 2009
    2009 Prognostic significance of VDR, DKK-1, and DKK-4 expression in colorectal cancer.Journal of Clinical Oncology.  27:e15047. 2009
    2009 Prognostic significance of p53 Codon 72 polymorphism differs with race in colorectal adenocarcinomaClinical Cancer Research.  15:2406-2416. 2009
    2009 Immunohistochemical expression of rabphilin -3A-like (Noc2) in normal and tumor tissues of human endocrine pancreas 2009
    2008 Lynch syndrome in women less than 50 years of age with endometrial cancerObstetrics and Gynecology.  111:1161-1166. 2008
    2008 p53 nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behavior 2008
    2008 Clinical significance of a novel single nucleotide polymorphism in the 5′ untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinomaFrontiers in Bioscience-Landmark.  13:1050-1061. 2008
    2007 The need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysisCancer Informatics.  1:86-97. 2007
    2007 Methionine inhibits cellular growth dependent on the p53 status of cells 2007
    2007 African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: An epidemiologic reviewCancer Biomarkers.  3:301-313. 2007
    2007 Comparison of predicted probabilities of proportional hazards regression and linear discriminant analysis methods using a colorectal cancer molecular biomarker databaseCancer Informatics.  3:115-122. 2007
    2007 Predicting 5-year survival of colorectal carcinoma patients using data mining methods.Proceedings / AMIA ... Annual Symposium. AMIA Symposium.  907. 2007
    2007 Understanding racial differences in colorectal cancer aids in individualized medicineFuture Oncology.  3:235-241. 2007
    2006 Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.American Journal of Clinical Pathology.  126:572-579. 2006
    2006 Mucinous expression in benign and neoplastic glandular lesions of the uterine cervixArchives of Pathology and Laboratory Medicine.  130:1510-1515. 2006
    2006 Phenotypic expression of Bax is a predictive marker of 5-fluorouracil treatment in colorectal cancer.Journal of Clinical Oncology.  24:3605. 2006
    2006 Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates: A translational research applicationAmerican Journal of Clinical Pathology.  126:572-579. 2006
    2006 Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations 2006
    2005 Keynote review: Recent advances in biomarkers for cancer diagnosis and treatmentDrug Discovery Today: BIOSILICO.  10:965-976. 2005
    2005 High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomasCancer.  103:2163-2170. 2005
    2005 Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinomaCancer Biomarkers.  1:241-250. 2005
    2004 Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma [2] (multiple letters)Cancer.  101:2899. 2004
    2004 Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinomaCancer.  101:66-76. 2004
    2004 Prognostic Significance of p27kip-1 Expression in Colorectal Adenocarcinomas Is Associated with Tumor StageClinical Cancer Research.  10:1743-1752. 2004
    2003 MUC1 and MUC2 Expression in Pancreatic Ductal Carcinoma Obtained by Fine-Needle AspirationCancer.  99:365-371. 2003
    2003 The efficacy of 9-Cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: Results of a randomized double-blind clinical trialCancer Epidemiology, Biomarkers and Prevention.  12:114-119. 2003
    2003 Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokersChest.  123:181-186. 2003
    2002 Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lungClinical Cancer Research.  8:734-744. 2002
    2002 Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in VitroAnalytical Biochemistry.  301:189-199. 2002
    2002 Molecular staging of colorectal cancer in African-American and caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 and p27kip-1International Journal of Cancer.  97:403-409. 2002
    2001 Altered subcellular localization of Suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomasClinical Cancer Research.  7:3495-3503. 2001
    2001 Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers. 2001
    2001 Molecular characterization of colorectal neoplasia in translational researchArchives of Pathology and Laboratory Medicine.  125:91-98. 2001
    2001 Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands 2001
    2000 Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomasClinical Cancer Research.  6:4017-4025. 2000
    2000 BC1-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomasInternational Journal of Cancer.  89:423-430. 2000
    2000 Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas.International Journal of Cancer.  89:423-430. 2000
    2000 Elevated expression of fatty acid synthase (FASE) in squamous cell cancer of the lung. 2000
    2000 Immunohistochemical evaluation of global DNA methylation: Comparison with in vitro radiolabeled methyl incorporation assay 2000
    2000 The expression of Ep-CAM (17-1A) in squamous cell cancers of the lungHuman Pathology.  31:482-487. 2000
    2000 The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lungHuman Pathology.  31:1068-1073. 2000
    1999 Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinomaInternational Journal of Cancer.  82:424-429. 1999
    1999 Evaluation of biomarker modulation by fenretinide in prostate cancer patientsEuropean Urology.  35:429-438. 1999
    1999 Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinomaInvestigative urology.  161:945-949. 1999
    1999 Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasiaInvestigative urology.  162:1462-1466. 1999
    1998 Nuclear accumulation of p53 in colorectal adenocarcinoma prognostic importance differs with race and location of the tumorCancer.  83:2456-2467. 1998
    1997 Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinomaInternational Journal of Cancer.  74:346-358. 1997
    1997 Re: loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. 1997
    1997 The use of biomarker expression to characterize neoplastic processes 1997


    Year Title Altmetric
    2017 Prognostic and predictive biomarkers for colorectal cancer.  151-162. 2017
    2012 Development and progression of colorectal neoplasia.  235-265. 2012

    Research Overview

  • Translational research in grastrointestinal malignancies and breast cancer - Dr. Manne’s present efforts are focused on population-based translational research for human neoplasias, with emphasis on colorectal and breast cancers. His laboratory, with projects funded by the National Cancer Institute and the Susan G. Komen Foundation, is evaluating molecular markers to identify aggressive phenotypic features of tumors to predict the efficacy of chemotherapeutic regimens and to assess clinical outcomes. Dr. Manne’s research and collaborative groups include experts in the fields of molecular biology, clinical oncology, pathology, epidemiology, statistics, and bioinformatics. For evaluating the clinical utility of genetic and phenotypic abnormalities in colorectal cancer, his group has developed strategies demonstrating that the utility of molecular biomarkers varies according to the anatomic location of tumors within the colorectum and with tumor stage, race/ethnicity, age, and gender. To validate the clinical utility of genetic and phenotypic markers, Dr. Manne’s laboratory is evaluating hundreds of colorectal cancer samples derived from African American and non-Hispanic Caucasian ethnic/racial backgrounds and collected from different institutions. Established molecular markers with be merged with other epidemiological, environmental, and socio-economic features to find the basis for racial disparities in colorectal and breast malignancies. Results from approaches involving biomarker discovery and bioinformatics will aid in developing predictive models specific for individual patients. The research interests of Dr. Manne also include use of genomics and proteomics for identification of early markers of cancers, specifically, identification of molecular signatures of benign colonic epithelium, which is at risk of developing colorectal neoplasias, and of other pre-malignant lesions. These studies will aid in the evaluation of molecular and pathologic characteristics of specimens and in the development of assays that relate to early detection, diagnosis, prognosis, and treatment of cancers.

    Keywords - Colorectal Cancer, Breast Cancer, Molecular Biomarkers, Racial/Ethnic Disparities, Cancer Control & Prevention
  • Principal Investigator On

  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership - Administrative Core  awarded by National Cancer Institute/NIH/DHHS
  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership - Pilot Project #1  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership - Research Projects  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership - Admin Core  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Tissue Procurement Shared Facility  awarded by National Cancer Institute/NIH/DHHS
  • EDRN Project-Prognostic Markers in Lynch Syndrome Colorectal Cancers  awarded by CREIGHTON UNIVERSITY
  • Effects of NefM1 Peptide on Primary and Metastatic Colorectal Cancer Xenografts  awarded by Michigan State University
  • Hedgehog/Gli1- Targeted Therapies to Overcome Ovarian Cancer Chemoresistance and Disease Recurrence  awarded by TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership: (Admin Supplement) to Support Development of PDX at UAB CCC  awarded by National Cancer Institute/NIH/DHHS
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership: Administrative Core  awarded by National Cancer Institute/NIH/DHHS
  • Predictive Molecular Markers of Colorectal Cancer  awarded by National Cancer Institute/NIH/DHHS
  • Safer Approaches to Colorectal Cancer Chemoprevention  awarded by BOARD OF TRUSTEES OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
  • Education And Training

  • Doctor of Philosophy in Zoology / Animal Biology, Osmania University 1987
  • Full Name

  • Upender Manne